TrialMultiple sclerosis (Houndmills, Basingstoke, England)2012

Predictive nature of IgM anti-α-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: a BENEFIT study analysis.

M S Freedman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.